Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The “living drug” consists of tumor-infiltrating lymphocytes that can recognize and attack a patient’s specific cancer.
A conversation with Dr. Alexandra-Chloé Villani about side effects experienced by melanoma patients undergoing immunotherapy
Patients who used adjuvant Keytruda had a reduced risk of recurrence and a 38% lower risk of death.
Combining Imfinzi and Avastin with TACE led to better treatment outcomes.
Following a single dose of Keytruda, scans were able to show metabolic changes in tumors that correlated with longer survival.
The FDA is investigating the risk of new T-cell malignancies among patients receiving the engineered T cells, but so far, cases are rare.
The Leukemia & Lymphoma Society’s Lee Greenberger rounds up exciting study results from ASH 2023 and emerging themes for the future.
Fred Hutch scientists prevent metastasis by boosting cancer-killing T cells in patients, primarily those with breast cancer.
We all have trillions of microorganisms that live throughout our bodies.
Stopping a treatment regimen that’s working can make patients nervous that the benefits will stop as well.
Toripalimab (Loqtorzi) is the first immunotherapy drug approved for nasopharyngeal carcinoma, a type of head and neck cancer.
Lack of awareness of and participation in clinical trials are the biggest obstacles to bringing new skin cancer therapies to market.
A look back at the most widely read science and treatment news we covered this year.
Progression-free survival rates were similar whether or not patients discontinued checkpoint inhibitors after remission.
The combination regimen improved overall survival by more than 50% compared with chemotherapy.
NCI-MATCH closed this year, as three new precision medicine trials — ComboMATCH, MyeloMATCH and iMATCH — are getting underway.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.